Literature DB >> 26415041

Intrathecal Acetyl-L-Carnitine Protects Tissue and Improves Function after a Mild Contusive Spinal Cord Injury in Rats.

Eric E Ewan1, Theo Hagg1.   

Abstract

Primary and secondary ischemia after spinal cord injury (SCI) contributes to tissue and axon degeneration, which may result from decreased energy substrate availability for cellular and axonal mitochondrial adenosine triphosphate (ATP) production. Therefore, providing spinal tissue with an alternative energy substrate during ischemia may be neuroprotective after SCI. To assess this, rats received a mild contusive SCI (120 kdyn, Infinite Horizons impactor) at thoracic level 9 (T9), which causes loss of ∼ 80% of the ascending sensory dorsal column axonal projections to the gracile nucleus. Immediately afterwards, the energy substrate acetyl-L-carnitine (ALC; 1 mg/day) or phosphate-buffered saline (PBS) was infused intrathecally (sub-arachnoid) for 6 days via an L5/6 catheter attached to a subcutaneous Alzet pump. ALC treatment improved overground locomotor function (Basso-Beattie-Breshnahan [BBB] score 18 vs. 13) at 6 days, total spared epicenter (71% vs. 57%) and penumbra white matter (90% vs. 85%), ventral penumbra microvessels (108% vs. 79%), and penumbra motor neurons (42% vs. 15%) at 15 days post-SCI, compared with PBS treatment. However, the ascending sensory projections (anterogradely traced with cholera toxin B from the sciatic nerves) and dorsal column white matter and perfused blood vessels were not protected. Furthermore, grid walking, a task we have shown to be dependent on dorsal column function, was not improved. Thus, mitochondrial substrate replacement may only be efficacious in areas of lesser or temporary ischemia, such as the ventral spinal cord and injury penumbra in this study. The current data also support our previous evidence that microvessel loss is central to secondary tissue degeneration.

Entities:  

Keywords:  ALC; axon; contusion; dorsal column; ischemia; mitochondria; spinal cord injury

Mesh:

Substances:

Year:  2015        PMID: 26415041      PMCID: PMC4744884          DOI: 10.1089/neu.2015.4030

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  38 in total

Review 1.  Degenerative and spontaneous regenerative processes after spinal cord injury.

Authors:  Theo Hagg; Martin Oudega
Journal:  J Neurotrauma       Date:  2006 Mar-Apr       Impact factor: 5.269

2.  Acetyl-L-carnitine treatment following spinal cord injury improves mitochondrial function correlated with remarkable tissue sparing and functional recovery.

Authors:  S P Patel; P G Sullivan; T S Lyttle; D S K Magnuson; A G Rabchevsky
Journal:  Neuroscience       Date:  2012-03-15       Impact factor: 3.590

3.  Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains.

Authors:  D Michele Basso; Lesley C Fisher; Aileen J Anderson; Lyn B Jakeman; Dana M McTigue; Phillip G Popovich
Journal:  J Neurotrauma       Date:  2006-05       Impact factor: 5.269

Review 4.  Blood supply and vascular reactivity of the spinal cord under normal and pathological conditions.

Authors:  Nikolay L Martirosyan; Jeanne S Feuerstein; Nicholas Theodore; Daniel D Cavalcanti; Robert F Spetzler; Mark C Preul
Journal:  J Neurosurg Spine       Date:  2011-06-10

5.  Rescuing vasculature with intravenous angiopoietin-1 and alpha v beta 3 integrin peptide is protective after spinal cord injury.

Authors:  Shu Han; Sheila A Arnold; Srinivas D Sithu; Edward T Mahoney; Justin T Geralds; Phuong Tran; Richard L Benton; Melissa A Maddie; Stanley E D'Souza; Scott R Whittemore; Theo Hagg
Journal:  Brain       Date:  2010-04       Impact factor: 13.501

6.  Dorsal column sensory axons lack TrkC and are not rescued by local neurotrophin-3 infusions following spinal cord contusion in adult rats.

Authors:  K Adam Baker; Shojiro Nakashima; Theo Hagg
Journal:  Exp Neurol       Date:  2007-01-25       Impact factor: 5.330

7.  Spinal cord contusion based on precise vertebral stabilization and tissue displacement measured by combined assessment to discriminate small functional differences.

Authors:  Yi Ping Zhang; Darlene A Burke; Lisa B E Shields; Sergey Y Chekmenev; Toros Dincman; Yongjie Zhang; Yiyan Zheng; Rebecca R Smith; Richard L Benton; William H DeVries; Xiaoling Hu; David S K Magnuson; Scott R Whittemore; Christopher B Shields
Journal:  J Neurotrauma       Date:  2008-10       Impact factor: 5.269

8.  Griffonia simplicifolia isolectin B4 identifies a specific subpopulation of angiogenic blood vessels following contusive spinal cord injury in the adult mouse.

Authors:  Richard L Benton; Melissa A Maddie; Danielle R Minnillo; Theo Hagg; Scott R Whittemore
Journal:  J Comp Neurol       Date:  2008-03-01       Impact factor: 3.215

9.  Small-molecule protein tyrosine phosphatase inhibition as a neuroprotective treatment after spinal cord injury in adult rats.

Authors:  Shojiro Nakashima; Sheila A Arnold; Edward T Mahoney; Srinivas D Sithu; Y Ping Zhang; Stanley E D'Souza; Christopher B Shields; Theo Hagg
Journal:  J Neurosci       Date:  2008-07-16       Impact factor: 6.167

10.  Neuroprotective effects of N-acetyl-cysteine and acetyl-L-carnitine after spinal cord injury in adult rats.

Authors:  Amar Karalija; Liudmila N Novikova; Paul J Kingham; Mikael Wiberg; Lev N Novikov
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

View more
  2 in total

1.  Reduced FAK-STAT3 signaling contributes to ER stress-induced mitochondrial dysfunction and death in endothelial cells.

Authors:  Kalpita Banerjee; Matt P Keasey; Vladislav Razskazovskiy; Nishant P Visavadiya; Cuihong Jia; Theo Hagg
Journal:  Cell Signal       Date:  2017-05-08       Impact factor: 4.315

Review 2.  Nanofiber Scaffolds as Drug Delivery Systems to Bridge Spinal Cord Injury.

Authors:  Angela Faccendini; Barbara Vigani; Silvia Rossi; Giuseppina Sandri; Maria Cristina Bonferoni; Carla Marcella Caramella; Franca Ferrari
Journal:  Pharmaceuticals (Basel)       Date:  2017-07-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.